Efficacy of escalating therapy with brentuximab vedotin-AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD.
Hematol Oncol
; 42(5): e3299, 2024 Sep.
Article
en En
| MEDLINE
| ID: mdl-39132926
ABSTRACT
Patients with advanced-stage Hodgkin lymphoma treated with ABVD who have a positive interim FDG-PET (iPET) have a poor prognosis. Escalation to BEACOPP has been shown to improve progression-free survival (PFS). However, randomized trials are lacking to determine the best strategy for intensification. We report on A-AVD escalation treatment outcomes for 15 iPET-positive patients post-ABVD. Overall response and complete response rates were 80% and 60%, respectively. Four patients underwent salvage therapy followed by autologous stem cell transplantation. At a median 17-month follow-up, all patients are alive, 87% in complete remission, and 1-year PFS was 57.8%. For patients ineligible for BEACOPP due to age, comorbidities, or preference, A-AVD escalation may be a viable alternative.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Vinblastina
/
Bleomicina
/
Enfermedad de Hodgkin
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Doxorrubicina
/
Dacarbazina
/
Tomografía de Emisión de Positrones
/
Brentuximab Vedotina
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Hematol Oncol
Año:
2024
Tipo del documento:
Article
País de afiliación:
España